select trial semaglutide ppt in kidney outcomes Obesity Patient.pptx Therapy for HFpEF: A step

Chronic Kidney Disease (CKD) and Diabetes patients on insulin

A 2024 study in the Journal of Managed Care + Specialty Pharmacy examined the effectiveness of GLP-1 therapy in the setting of weight management and found that only one-third of individuals took their medications as prescribed

As of March 2026, just 13 state Medicaid programs cover GLP-1 medications, including Ozempic, for obesity treatment: Delaware Kansas Massachusetts Michigan Minnesota Mississippi Missouri North Carolina Rhode Island Tennessee Utah Virginia Wisconsin Medicaid programs in California, New Hampshire, Pennsylvania, and South Carolina all recently ended obesity drug coverage, citing the steep cost of these medications

No in-person exam is required